Loss of presenilin function causes Alzheimer's disease‐like neurodegeneration in the mouse
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Accumulating evidence has indicated that gain‐of‐function in β‐amyloid production may be not the necessary mechanism for mutant presenilin‐1 (PS1) or PS2 to cause familial Alzheimer's disease (AD). In the present article, we show that conditional knockout of PS1 from the adult stage in the forebrain of mice with the PS2 null mutation triggers robust AD‐like neurodegeneration including brain shrinkage, cortical and hippocampal atrophy,ventricular enlargement, severe neuronal loss, gliosis, tau hyperphosphorylation, neurofillament tangle‐like structures, and intracellular filaments. Learning and memory functions in these mice are almost completely lost. Notably, there is no β‐amyloid deposition, indicating that presenilin dysfunction can directly cause neurodegeneration without the involvement of β‐amyloid. Furthermore, neurodegeneration occurs in a progressive manner following aging, suggesting that an accumulating effect of presenilin dysfunction over time might be a pathogenic mechanism for the involvement of mutant PS1/PS2 in causing AD. These results validate a mouse model characterized by the presence of many features of AD pathology. Furthermore, the demonstration of AD‐like neurodegeneration in the absence of β‐amyloid deposition challenges the long‐standing β‐amyloid cascade hypothesis and encourages an open debate on the role of β‐amyloid in causing AD. Most important, our results strongly suggest that to develop γ‐secretase inhibitors for the pharmacological treatment of AD may be not a reasonable strategy because antagonism of presenilin function may worsen neurodegeneration. © 2008 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769 · cited 1×
“Recently, it has also been found that a shift from Ab aggregation to a soluble or oligomeric state of Ab might be a reason for neuronal dysfunction (Lesne et al., 2006).”
BackgroundRetractedOakley, H., Cole, S. L., Logan, S., Maus, E., Shao, P., Craft, J., Guillozet-Bongaarts, A., Ohno, M., Disterhoft, J., Van Eldik, L., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.1202-06.2006 · Cited by 3,530 · cited 2×
“, 2006), APP/multiple PS mutations (Oakley et al., 2006), or direct expression of Ab peptide (McGowan et al.”
BackgroundScheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., et al. (1996) · Nature Medicine · doi:10.1038/nm0896-864 · Cited by 2,599 · cited 1×
“Indeed, a huge body of evidence has shown that FAD-linked PS1 variants have this abnormal gain-offunction property (Citron et al., 1992; Borchelt et al., 1996; Scheuner et al., 1996).”
BackgroundRogaev, E. I., Sherrington, R., Rogaeva, E. A., Levesque, G., Ikeda, M., Liang, Y., Chi, H., Lin, C., Holman, K., Tsuda, T., et al. (1995) · Nature · doi:10.1038/376775a0 · Cited by 2,052 · cited 1×
“In the case of familial type of AD (FAD), at least three genes, b-amyloid precursor protein (APP), PS1, and PS2, have been identified as causative genes (Campion et al., 1995; Rogaev et al., 1995; Sherrington et al., 1995).”
BackgroundTwenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective
Tanzi, R. E., & Bertram, L. (2005) · Cell · doi:10.1016/j.cell.2005.02.008 · Cited by 1,849
Citron, M., Oltersdorf, T., Haass, C., McConlogue, L., Hung, A. Y., Seubert, P., Vigo-Pelfrey, C., Lieberburg, I., & Selkoe, D. J. (1992) · Nature · doi:10.1038/360672a0 · Cited by 1,757 · cited 1×
“Indeed, a huge body of evidence has shown that FAD-linked PS1 variants have this abnormal gain-offunction property (Citron et al., 1992; Borchelt et al., 1996; Scheuner et al., 1996).”
BackgroundEnhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP
Lewis, J., Dickson, D. W., Lin, W.-L., Chisholm, L., Corral, A., Jones, G., Yen, S.-H., Sahara, N., Skipper, L., Yager, D., et al. (2001) · Science · doi:10.1126/science.1058189 · Cited by 1,611 · cited 3×
“These NFT-like structures appeared to be morphologically similar to those observed in AD patients (Lewis et al., 2001).”
BackgroundResultNeuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease
Gómez‐Isla, T., Hollister, R., West, H., Mui, S., Growdon, J. H., Petersen, R. C., Parisi, J. E., & Hyman, B. T. (1997) · Annals of Neurology · doi:10.1002/ana.410410106 · Cited by 1,489 · cited 1×
“In some vulnerable brain regions, such as certain cortical areas, more than 50% or even up to 70%–90% of neurons are lost (Gomez-Isla et al., 1997; Bussiere et al., 2003).”
BackgroundBorchelt, D. R., Thinakaran, G., Eckman, C. B., Lee, M. K., Davenport, F., Ratovitsky, T., Prada, C.-M., Kim, G., Seekins, S., Yager, D., et al. (1996) · Neuron · doi:10.1016/s0896-6273(00)80230-5 · Cited by 1,478
Lewis, J., McGowan, E., Rockwood, J., Melrose, H., Nacharaju, P., Van Slegtenhorst, M., Gwinn-Hardy, K., Murphy, M. P., Baker, M., Yu, X., et al. (2000) · Nature Genetics · doi:10.1038/78078 · Cited by 1,371 · cited 2×
“…compared to that in mutant APP/PS1 transgenic mice, relatively more severe AD neurodegeneration was observed in transgenic mice expressing other AD risk genes such as tau (Lewis et al., 2000) or especially both APP/PS1 and tau (Lewis et al., 2001; Oddo et al., 2003; Ribe et al., 2005).”
BackgroundNeurotoxicity of a Fragment of the Amyloid Precursor Associated with Alzheimer's Disease
Yankner, B. A., Dawes, L. R., Fisher, S., Villa-Komaroff, L., Oster-Granite, M. L., & Neve, R. L. (1989) · Science · doi:10.1126/science.2474201 · Cited by 907
Saura, C. A., Choi, S.-Y., Beglopoulos, V., Malkani, S., Zhang, D., Rao, B. S. S., Chattarji, S., Kelleher, R. J., Kandel, E. R., Duff, K., et al. (2004) · Neuron · doi:10.1016/s0896-6273(04)00182-5 · Cited by 757 · cited 1×
“In their studies, however, they primarily focused on synaptic function and the apoptotic pathway associated with neurodegeneration (Feng et al., 2004, Saura et al., 2004, respectively).”
BackgroundSelf-citationA learning deficit related to age and β-amyloid plaques in a mouse model of Alzheimer's disease
Chen, G., Chen, K. S., Knox, J., Inglis, J., Bernard, A., Martin, S. J., Justice, A., McConlogue, L., Games, D., Freedman, S. B., et al. (2000) · Nature · doi:10.1038/35050103 · Cited by 740
Aβ42 Is Essential for Parenchymal and Vascular Amyloid Deposition in Mice
McGowan, E., Pickford, F., Kim, J., Onstead, L., Eriksen, J., Yu, C., Skipper, L., Murphy, M. P., Beard, J., Das, P., et al. (2005) · Neuron · doi:10.1016/j.neuron.2005.06.030 · Cited by 637 · cited 5×
“, 2003), in general without the presence of NFTs, especially without comparable ADlike neuronal loss (Irizarry et al., 1997; Calhoun et al., 1998; Redwine et al., 2003; McGowan et al., 2005), although a longevity factor has been suggested as a potential reason for this absence of full AD pathology (Geula et al.”
BackgroundInfluentialThe disease progression of Mecp2 mutant mice is affected by the level of BDNF expression
Chang, Q., Khare, G., Dani, V., Nelson, S., & Jaenisch, R. (2006) · Neuron · doi:10.1016/j.neuron.2005.12.027 · Cited by 578 · cited 2×
“As we think that AD neurodegeneration is an outcome of a pathogenic effect over time, the failure to reproduce AD-like neurodegeneration in mice with extremely high deposition of Ab may tell us that Ab deposition may be not pathogenic per se, especially given that robust neuronal loss can be readily produced in the mo…”
BackgroundAging renders the brain vulnerable to amyloid β-protein neurotoxicity
Guela, C., Wu, C.-K., Saroff, D., Lorenzo, A., Yuan, M., & Yankner, B. A. (1998) · Nature Medicine · doi:10.1038/nm0798-827 · Cited by 520
γ-Secretase, notch, Aβ and alzheimer's disease: Where do the presenilins fit in?
Sisodia, S. S., & St George-Hyslop, P. H. (2002) · Nature Reviews Neuroscience · doi:10.1038/nrn785 · Cited by 512
Neuron loss in APP transgenic mice
Calhoun, M. E., Wiederhold, K.-H., Abramowski, D., Phinney, A. L., Probst, A., Sturchler-Pierrat, C., Staufenbiel, M., Sommer, B., & Jucker, M. (1998) · Nature · doi:10.1038/27351 · Cited by 502 · cited 2×
“, 2003), in general without the presence of NFTs, especially without comparable ADlike neuronal loss (Irizarry et al., 1997; Calhoun et al., 1998; Redwine et al., 2003; McGowan et al., 2005), although a longevity factor has been suggested as a potential reason for this absence of full AD pathology (Geula et al.”
BackgroundIrizarry, M. C., Soriano, F., McNamara, M., Page, K. J., Schenk, D., Games, D., & Hyman, B. T. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-18-07053.1997 · Cited by 497 · cited 2×
“, 2003), in general without the presence of NFTs, especially without comparable ADlike neuronal loss (Irizarry et al., 1997; Calhoun et al., 1998; Redwine et al., 2003; McGowan et al., 2005), although a longevity factor has been suggested as a potential reason for this absence of full AD pathology (Geula et al.”
BackgroundGuo, Q., Fu, W., Sopher, B. L., Miller, M. W., Ware, C. B., Martin, G. M., & Mattson, M. P. (1999) · Nature Medicine · doi:10.1038/4789 · Cited by 489
Shen, J., & Kelleher, R. J. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0608332104 · Cited by 485 · cited 1×
“Recently, it has been emphasized regarding the loss-of-function mechanism for the involvement of mutant PS1 in the pathogenesis of AD (Shen and Kelleher, 2007).”
BackgroundChui, D.-H., Tanahashi, H., Ozawa, K., Ikeda, S., Checler, F., Ueda, O., Suzuki, H., Araki, W., Inoue, H., Shirotani, K., et al. (1999) · Nature Medicine · doi:10.1038/8438 · Cited by 364 · cited 1×
“For example, FAD-linked mutant PS1 can directly result in neurodegeneration without Ab deposition (Chui et al., 1999).”
BackgroundEffects of PS1 Deficiency on Membrane Protein Trafficking in Neurons
Naruse, S., Thinakaran, G., Luo, J.-J., Kusiak, J. W., Tomita, T., Iwatsubo, T., Qian, X., Ginty, D. D., Price, D. L., Borchelt, D. R., et al. (1998) · Neuron · doi:10.1016/s0896-6273(00)80637-6 · Cited by 355 · cited 1×
“Interestingly, the results from knockout studies have revealed that these genes have a gradient of importance in neuronal development, with PS1 the most essential (Zheng et al., 1996; Naruse et al., 1998; Herreman et al., 1999); thus, PS1-FAD is the most aggressive and has the earliest onset.”
BackgroundBussière, T., Giannakopoulos, P., Bouras, C., Perl, D. P., Morrison, J. H., & Hof, P. R. (2003) · Journal of Comparative Neurology · doi:10.1002/cne.10760 · Cited by 185 · cited 1×
“In some vulnerable brain regions, such as certain cortical areas, more than 50% or even up to 70%–90% of neurons are lost (Gomez-Isla et al., 1997; Bussiere et al., 2003).”
BackgroundPresenilin-Dependent -Secretase-Mediated Control of p53-Associated Cell Death in Alzheimer's Disease
Alves da Costa, C., Sunyach, C., Pardossi-Piquard, R., Sevalle, J., Vincent, B., Boyer, N., Kawarai, T., Girardot, N., St. George-Hyslop, P., & Checler, F. (2006) · Journal of Neuroscience · doi:10.1523/jneurosci.0651-06.2006 · Cited by 168 · cited 1×
“…synaptic formation and function, and cell adhesion (Artavanis-Tsakonas et al., 1999; Sisodia and St George-Hyslop, 2002; Koo and Kopan, 2004; Alves da Costa et al., 2006; Beglopoulos and Shen, 2006; Doglio et al., 2006; Zatti et al., 2006), in addition to APP metabolism and Notch activation.”
Background
Cited by
Crespo-Barreto, J., Fryer, J. D., Shaw, C. A., Orr, H. T., & Zoghbi, H. Y. (2010) · PLoS Genetics · doi:10.1371/journal.pgen.1001021 · Cited by 136
“However, loss of function of presenilin in the mouse brain results in phenotypes strikingly reminiscent of AD (progressive memory loss and neurodegeneration) in the absence of beta-amyloid deposition [50,51].”
BackgroundNeely, K. M., Green, K. N., & LaFerla, F. M. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.5156-10.2010 · Cited by 134
MicroRNA Profiling in Aging Brain of PSEN1/PSEN2 Double Knockout Mice
Ham, S., Kim, T. K., Lee, S., Tang, Y.-P., & Im, H.-I. (2018) · Molecular Neurobiology · doi:10.1007/s12035-017-0753-6 · Cited by 12
Self-citation
Metadata
- Authors
- Chen, Q., Nakajima, A., Choi, S. H., Xiong, X., & Tang, Y.
- Venue
- Journal of Neuroscience Research
- Publisher
- Wiley
- Published
- 2008-01-11
- Volume
- 86
- Issue
- 7
- Pages
- 1615-1625
- ISSN
- 0360-4012 (ISSN-L)
- 1097-4547
- OpenAlex
- W2011625110
- Cited by
- 46
- References
- 25
- FWCI
- 4.22
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.